PTI-821: sustained-release oxycodone using gel-cap technology.

  title={PTI-821: sustained-release oxycodone using gel-cap technology.},
  author={Lynn R Webster},
  journal={Expert opinion on investigational drugs},
  volume={16 3},
  • Lynn R Webster
  • Published 2007 in Expert opinion on investigational drugs
PTI-821 is a long-acting formulation of oxycodone that is intended to deter abuse through its gel-cap technology. Produced by Pain Therapeutics in alliance with King Pharmaceuticals, PTI-821 is designed to provide strong pain relief with the intent of offering greater safety than is presently available from conventional controlled-release oxycodone products. This paper presents the available preliminary data on PTI-821 and discusses their potential clinical applications. The results of three… CONTINUE READING

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…